Fortress Biotech, Inc. - Jan 2, 2024 Form 4 Insider Report for MUSTANG BIO, INC. (MBIO)

Role
10%+ Owner
Signature
/s/ Samuel Berry, General Counsel and Authorized Agent
Stock symbol
MBIO
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 04:29 PM
Previous filing
Jan 3, 2024
Next filing
Mar 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBIO COMMON STOCK, PAR VALUE $0.0001 Award $0 +419K +27.78% $0.00 1.93M Jan 2, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
F2 The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 66,003 shares were granted by the Issuer to the Reporting Person following the closing of equity financings.
F3 The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 353,089 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend.